QUANTITATION OF A NEW POTENT ANGIOTENSIN-II RECEPTOR ANTAGONIST, TCV-116, AND ITS METABOLITES IN HUMAN SERUM AND URINE

A sensitive high-performance liquid chromatographic (HPLC) method is d escribed for the determination of a new potent antihypertensive agent, TCV-116, and its two metabolites (M-I and M-II) in human serum or uri ne. After pre-treatment of the specimens, the analytes were determined using a column switching technique, except for the metabolites in uri ne which were determined by gradient elution mode HPLC. The quantitati on limits for TCV-116, M-I and M-II were all 0.5 ng/ml in serum, and 0 .5, 10 and 10 ng/ml in urine, respectively. The methods were applied t o clinical trials of TCV-116.